Indian Peptide and Anticoagulant Drugs Market worth $883.0 Million and $170.2 Million by 2022

PUNE, India, 2020-May-25 — /EPR Network/ —

Indian Peptide Drugs Market

The Indian peptide drugs market is projected to reach USD 883.0 Million by 2022 from USD 381.8 Million in 2016, at a CAGR of 15.0%.

Increasing prevalence of chronic diseases such as cancer and diabetes and favorable government policies for the pharmaceutical sector are the major factors driving the growth of Indian peptide market.

Hormonal segment is expected to dominate the market in 2016

On the basis of type segmentation, The Indian peptide drugs market is classified into hormonal, antifungal, antibiotic, ACE inhibitor and others. The hormonal segment is expected to dominate the Indian peptide drugs market in 2016.

Growing incidence and prevalence rate of diabetes in India and rising ageing population are the major driving factors for this segment.

Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734

The diabetes segment is expected to dominate the market in 2016

Based on application, the indian peptide drugs market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological application, and other applications. In 2016, the diabetes segment is expected to account for the largest share of the Indian peptide drugs market, by application.

The growth in the segment can be primarily attributed to increasing incidence and prevalence of diabetes cases in the country.

Key Players

Some of the major players operating in the Indian peptide drugs market include Abbott Laboratories (US), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).

Indian Anticoagulant Drugs Market

The Indian anticoagulant drugs market to reach USD 170.2 Million in 2022 from USD 127.8 Million in 2016 and is expected to register a CAGR of 4.9%.

Factors such as incidence of coagulation disorders and government support for pharmaceutical companies are contributing to the growth of this market.

Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=77044734

Enoxaparin sodium segment is expected to dominate the market in 2016

On the basis of Low molecular weight heparin type, the Indian anticoagulant drugs market is classified into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium.

In 2016, the enoxaparin sodium segment is expected to account for the largest share of the Indian anticoagulant drugs market, by type. Enoxaparin sodium is available as an injectable that helps prevent blood clots in the leg veins of patients who have undergone hip/knee replacements or abdominal surgery.

According to Human Pharmaceuticals at Boehringer Ingelheim, in India, approximately 231,132 venous thromboembolism (VTE) procedures occur annually; 53.6% of hospitalized Indian patients are at an increased risk of VTE.

Key Players

Some of the major players operating in the Indian anticoagulant drugs market are Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).

Inquiry about Peptide and Anticoagulant Drugs Market before buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=77044734